Aster Capital Management’s Vir Biotechnology VIR Stock Holding History

Aster Capital Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$6	–	1271
2026 Q1	$6	Sell	1 -10	-91%	-$80	﹤0.01%	809
2025 Q4	$66	Buy	+11	New	+$65	﹤0.01%	1048
2025 Q2	–	Sell	-698	Closed	-$5.86K	–	1607
2025 Q1	$5.86K	Sell	698 -33,682	-98%	-$299K	﹤0.01%	1108
2024 Q4	$252K	Buy	34,380 +34,202	+19,215%	+$270K	0.1%	249
2024 Q3	$1.33K	Buy	+178	New	+$1.55K	﹤0.01%	996

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Aster Capital Management's VIR Position: Q2 2026 in Review

Aster Capital Management sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 1 share — an estimated $6 sold.

Aster Capital Management first reported a position in VIR in Q3 2024 and held it in 5 quarters. The position peaked at $252K in Q4 2024. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Aster Capital Management reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
Aster Capital Management sold 1 Vir Biotechnology share in Q2 2026, an estimated $6.
Aster Capital Management first reported a position in Vir Biotechnology in Q3 2024 and held it in 5 quarters.
Aster Capital Management's Vir Biotechnology position peaked at $252K in Q4 2024.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.